Asia-Pacific Colorectal Cancer Market to 2028 - Regional Analysis and Forecasts by Modality (Diagnosis Type, Therapy Type, Imaging Type); End User (Hospitals, Diagnostic and Research Laboratories), and Country

List of Tables

The colorectal cancer market in Asia Pacific is expected to grow from US$ 3,864.66 million in 2022 to US$ 5,169.04 million by 2028; it is estimated to grow at a CAGR of 3.7% from 2022 to 2028.

The growing pharmaceutical industry in emerging economies is creating lucrative opportunities for significant players to expand their businesses in the Asia Pacific colorectal cancer market. The pharmaceutical sector in India is expected to grow from US$ 42 billion in 2021 to US$ 55 billion by 2025; it is estimated to register at a CAGR of 37% from 2021 to 2025. According to India Brand Equity Foundation (IBEF) statistics in April 2019, India is the largest provider of generic drugs worldwide. The Indian pharmaceutical industry supplies ~40% of the generic demand in the US, with ~50% of the demand for multiple vaccines and 25% of all medicines in the UK. Moreover, India has a massive number of scientists and engineers with the potential to grow the healthcare industry remarkably.

Major colorectal cancer market players focus on emerging markets such as Singapore and China as they have many colorectal cancer patients, along with growing medical tourism. As per the Australian Institute of Health and Welfare, over ~15,540 new cases of colorectal cancer were diagnosed in 2021. Moreover, as per the Malaysia Healthcare Travel Council, in 2019, over 1.22 million travelers visited Malaysia for healthcare purposes. The low cost of treatment and incorporation of advanced technologies to provide less waiting time for procedures in Asia Pacific are likely to boost the number of surgeries associated with colorectal cancer. This ultimately increases the demand for colorectal cancer diagnostics and treatment.

Thus, the increasing medical tourism and the growing pharmaceutical industry in emerging countries are expected to boost the APAC colorectal cancer market growth; it is also anticipated to provide significant growth opportunities to the players operating in the market during the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific colorectal cancer market. The Asia Pacific colorectal cancer market is expected to grow at a substantial CAGR during the forecast period.

Asia Pacific Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Colorectal Cancer Market Segmentation

The Asia Pacific colorectal cancer market is segmented into modality, end user, and country. Based on modality, the Asia Pacific colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the Asia Pacific colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share. Based on country, the Asia Pacific colorectal cancer market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held the largest market share in 2022.

Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., EDP Biotech Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies in the Asia Pacific colorectal cancer market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific colorectal cancer market
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific colorectal cancer market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the colorectal cancer market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Product Code: TIPRE00009518

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 APAC Colorectal Cancer Market - By Modality
- 1.3.2 APAC Colorectal Cancer Market - By End User
- 1.3.3 APAC Colorectal Cancer Market - By Country

2. APAC Colorectal Cancer Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. APAC Colorectal Cancer- Market Landscape

4.1 Overview
4.2 APAC PEST Analysis
4.3 Expert Opinion

5. APAC Colorectal Cancer Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Colorectal Cancer
- 5.1.2 New Product Launches
- 5.1.3 Benefits Offered by Generic Drugs
5.2 Market Restraints
- 5.2.1 Pricing Pressure on Drug Manufacturers
5.3 Market Opportunities
- 5.3.1 Growing Pharmaceutical Industry in Emerging Economies
5.4 Future Trends
- 5.4.1 Inclination Toward Personalized Medicine
5.5 Impact Analysis

6. APAC Colorectal Cancer Market- APAC Analysis

6.1 APAC Colorectal Cancer Market Revenue Forecast and Analysis
- 6.1.1 Overview

7. APAC Colorectal Cancer Market Analysis - By Modality

7.1 Overview
7.2 APAC Colorectal Cancer Market Revenue Share, By Modality 2022 & 2028 (%)
7.3 Diagnosis Type
- 7.3.1 Overview
- 7.3.2 Diagnosis Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.3 Immunohistochemistry
  - 7.3.3.1 Overview
  - 7.3.3.2 Immunohistochemistry: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.4 Stool Test
  - 7.3.4.1 Overview
  - 7.3.4.2 Stool Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.5 Flexible Sigmoidoscopy
  - 7.3.5.1 Overview
  - 7.3.5.2 Flexible Sigmoidoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.6 Colonoscopy
  - 7.3.6.1 Overview
  - 7.3.6.2 Colonoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.7 CEA Test
  - 7.3.7.1 Overview
  - 7.3.7.2 CEA Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.3.8 Other Test
  - 7.3.8.1 Overview
  - 7.3.8.2 Other Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Therapy Type
- 7.4.1 Overview
- 7.4.2 APAC Therapy Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.3 Chemotherapy
  - 7.4.3.1 Overview
  - 7.4.3.2 Chemotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.3.3 Alkylating Agent
    - 7.4.3.3.1 Overview
    - 7.4.3.3.2 Alkylating Agent: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.3.4 Antimetabolites
    - 7.4.3.4.1 Antimetabolites: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.3.5 Others
    - 7.4.3.5.1 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.4 Immunotherapy
  - 7.4.4.1 Overview
  - 7.4.4.2 Immunotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.3 Panitumumab
    - 7.4.4.3.1 Overview
    - 7.4.4.3.2 Panitumumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.4 Cetuximab
    - 7.4.4.4.1 Overview
    - 7.4.4.4.2 Cetuximab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.5 Bevacizumab
    - 7.4.4.5.1 Overview
    - 7.4.4.5.2 Bevacizumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.4.6 Others
    - 7.4.4.6.1 Overview
    - 7.4.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.5 Chemoprotectant
  - 7.4.5.1 Overview
  - 7.4.5.2 Chemoprotectant: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4.6 Others
  - 7.4.6.1 Overview
  - 7.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Imaging Type
- 7.5.1 Overview
- 7.5.2 APAC Imaging Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5.3 Computed Tomography (CT)
  - 7.5.3.1 Overview
  - 7.5.3.2 Computed Tomography (CT) : Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5.4 Magnetic Resonance Imaging (MRI)
  - 7.5.4.1 Overview
  - 7.5.4.2 Magnetic Resonance Imaging (MRI): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5.5 Others
  - 7.5.5.1 Overview
  - 7.5.5.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)

8. APAC Colorectal Cancer Market Revenue and Forecast To 2028 - By End User

8.1 Overview
8.2 APAC Colorectal Cancer Market Revenue Share, By End User 2022 & 2028 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Diagnostic and Research Laboratories
- 8.4.1 Overview
- 8.4.2 Diagnostic and Research Laboratories: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)

9. APAC Colorectal Cancer Market Revenue and Forecast to 2028 - Country Analysis

9.1 Overview
- 9.1.1 APAC Colorectal Cancer Market Revenue and Forecasts to 2028, By Country (%)
  - 9.1.1.1 China Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
    - 9.1.1.1.1 China Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.1.2 China: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.1.1.2.1 China: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.1.1.2.2 China: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.1.1.2.2.1 China: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.1.2.2.2 China: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.1.2.3 China: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
    - 9.1.1.1.3 China: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.1.2 Japan Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.2.1 Japan Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.2.2 Japan: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.1.2.2.1 Japan: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.1.2.2.2 Japan: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.1.2.2.2.1 Japan: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.2.2.2.2 Japan: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.2.2.3 Japan: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
    - 9.1.1.2.3 Japan : Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.1.3 India Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.3.1 India Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.3.2 India: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.1.3.2.1 India: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.1.3.2.2 India: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.1.3.2.2.1 India: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.3.2.2.2 India: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.3.2.3 India: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
    - 9.1.1.3.3 India : Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.1.4 South Korea Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
    - 9.1.1.4.1 South Korea Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.4.2 South Korea: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.1.4.2.1 South Korea: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.1.4.2.2 South Korea: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.1.4.2.2.1 South Korea: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.4.2.2.2 South Korea: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.4.2.3 South Korea: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
    - 9.1.1.4.3 South Korea : Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.1.5 Australia Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.5.1 Australia Colorectal Cancer Market Revenue and Forecasts To 2028 (US$ Million)
    - 9.1.1.5.2 Australia: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.1.5.2.1 Australia: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.1.5.2.2 Australia: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.1.5.2.2.1 Australia: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.5.2.2.2 Australia: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.5.2.3 Australia: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
    - 9.1.1.5.3 Australia : Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
  - 9.1.1.6 Rest of APAC: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
    - 9.1.1.6.1 Overview
    - 9.1.1.6.2 Rest of APAC: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)
    - 9.1.1.6.3 Rest of APAC:: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
    - 9.1.1.6.3.1 Rest of APAC: Colorectal Cancer Market, by Diagnosis Type - 2019-2028 (US$ Million)
    - 9.1.1.6.3.2 Rest of APAC: Colorectal Cancer Market, by Therapy Type- 2019- 2028 (US$ Million)
    - 9.1.1.6.3.2.1 Rest of APAC: Colorectal Cancer Market, by Chemotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.6.3.2.2 Rest of APAC: Colorectal Cancer Market, by Immunotherapy- 2019- 2028 (US$ Million)
    - 9.1.1.6.3.3 Rest of APAC: Colorectal Cancer Market, by Imaging Type- 2019- 2028 (US$ Million)
    - 9.1.1.6.4 Rest of APAC: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)

10. Colorectal Cancer Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies In The Colorectal Cancer Market, 2022-2028
10.3 Organic Developments
- 10.3.1 Overview
- 10.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2022-2028
10.4 Inorganic Developments
- 10.4.1 Overview
- 10.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2022-2028

11. Company Profiles

11.1 Epigenomics AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Clinical Genomics Technologies Pty. Ltd.
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Abbott
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Amgen Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 F. HOFFMANN-LA ROCHE LTD.
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bruker Corporation
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Quest Diagnostics Incorporated
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 EDP Biotech Corporation
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Volitionrx Limited
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms